Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

31.03.2022 | short review

Breast Cancer—Essential news of current guidelines

verfasst von: MD, MBA Kathrin Strasser-Weippl

Erschienen in: memo - Magazine of European Medical Oncology

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The treatment of breast cancer is constantly evolving, making it hard for oncologists to be up-to-date with all aspects of the disease. Guidelines summarizing the current treatment standard for different clinical scenarios may be used to overcome these challenges. There are several guidelines that can be used in clinical practice: The NCCN guidelines, most widely known around the world, are very up-to-date and cover all treatment options for a wide range of scenarios using decision trees. The German S3-guidelines are text-based and include levels of evidence and grades of recommendation. Those of the German ‘Arbeitsgemeinschaft für Gynäkologische Onkologie‘ (AGO) in addition provide short summaries of recent publications to support the recommendations. The St. Gallen recommendations for early breast cancer are consensus-based and very interdisciplinary. And finally, the ESMO guidelines for advanced breast cancer most recently include the ESMO Scale for a Actionability of Molecular Targets (ESMO-ESCAT), which helps in deciding which molecular test to use with respect to treatment decisions.
Most guidelines are very up-to-date and may be a helpful in clinical decision-making. However, one should never forget that the complexity of clinical scenarios goes beyond the factors that can be mapped in guidelines. This also includes, for example, age, comorbidities and, last but not least, our patients’ preferences.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
4.
Zurück zum Zitat Thomssen C, Balic M, Harbeck N, Gnant M. St. Gallen/Vienna 2021: A brief summary of the consensus discussion on customizing therapies for women with early breast cancer. Breast Care. 2021;16(2):135–43. CrossRef Thomssen C, Balic M, Harbeck N, Gnant M. St. Gallen/Vienna 2021: A brief summary of the consensus discussion on customizing therapies for women with early breast cancer. Breast Care. 2021;16(2):135–43. CrossRef
5.
Zurück zum Zitat Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95. CrossRef Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95. CrossRef
6.
Zurück zum Zitat Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49. CrossRef Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49. CrossRef
7.
Zurück zum Zitat Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–66. CrossRef Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–66. CrossRef
8.
Zurück zum Zitat Condorelli R, Mosele F, Verret B, et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2019;30(3):365–73. CrossRef Condorelli R, Mosele F, Verret B, et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2019;30(3):365–73. CrossRef
9.
Zurück zum Zitat Cardoso F, Kyriakides S, Ohno S, et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–220. CrossRef Cardoso F, Kyriakides S, Ohno S, et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–220. CrossRef
10.
Zurück zum Zitat Johnston SRD, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987–98. CrossRef Johnston SRD, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987–98. CrossRef
11.
Zurück zum Zitat J. O’Shaughnessy et al. Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE #VP8_2021, ESMO Virtual Plenary, 14 Oct 2021 J. O’Shaughnessy et al. Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE #VP8_2021, ESMO Virtual Plenary, 14 Oct 2021
12.
Zurück zum Zitat Schmid, P. et al. KEYNOTE-522: Phase-3-Studie zu Pembrolizumab + Chemotherapie vs. Placebo + Chemotherapie als neoadjuvante Behandlung, gefolgt von Pembrolizumab vs. Placebo als adjuvante Behandlung bei frühem dreifach negativem Brustkrebs (TNBC). #VP7_2021, ESMO Virtual Plenary Debate, 17 Sept 2021 Schmid, P. et al. KEYNOTE-522: Phase-3-Studie zu Pembrolizumab + Chemotherapie vs. Placebo + Chemotherapie als neoadjuvante Behandlung, gefolgt von Pembrolizumab vs. Placebo als adjuvante Behandlung bei frühem dreifach negativem Brustkrebs (TNBC). #VP7_2021, ESMO Virtual Plenary Debate, 17 Sept 2021
13.
Zurück zum Zitat Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–28. CrossRef Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–28. CrossRef
14.
Zurück zum Zitat Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–51. CrossRef Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–51. CrossRef
15.
Zurück zum Zitat Cortés, J. et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. ESMO Congress 2021, #LBA1, Presidential symposium 1, 18 Sept 2021 Cortés, J. et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. ESMO Congress 2021, #LBA1, Presidential symposium 1, 18 Sept 2021
Metadaten
Titel
Breast Cancer—Essential news of current guidelines
verfasst von
MD, MBA Kathrin Strasser-Weippl
Publikationsdatum
31.03.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00799-5